Xilio Therapeutics, Inc.
Recent Filings
All 326 filings →| Form | Description | Date |
|---|---|---|
| S-8 | S-8 | Mar 23, 2026 |
| 10-K | 10-K | Mar 23, 2026 |
| 8-K | 8-K | Mar 23, 2026 |
| 8-K | 8-K | Mar 12, 2026 |
| 8-K | 8-K | Mar 9, 2026 |
| 8-K | 8-K | Feb 24, 2026 |
| SCHEDULE 13G/A | — | Feb 17, 2026 |
| SCHEDULE 13G/A | — | Feb 17, 2026 |
| SCHEDULE 13G/A | — | Feb 13, 2026 |
| 8-K | 8-K | Feb 12, 2026 |
Insider Transactions
View all →| Insider | Title | Type | Shares | Owns After | Date |
|---|---|---|---|---|---|
| Shannon James Samuel | — | Purchase | 25,000 @ $0.69 | 70,000 | Jun 16, 2025 |
| Russo Rene | PRESIDENT AND CEO | Purchase | 36,289 @ $0.68 | 281,172 | Jun 16, 2025 |
| Frankenfield Christopher James | Chief Financial Officer | Sale | 6,954 @ $0.98 | 12,421 | Jan 1, 2025 |
| GILEAD SCIENCES, INC. | — | Purchase | 1,759,978 @ $1.04 | 9,105,451 | Dec 18, 2024 |
| GILEAD SCIENCES, INC. | — | Purchase | 485,250 @ $0.76 | 7,345,473 | Apr 2, 2024 |
| Atlas Venture Fund XI, L.P. | — | Sale | 733 @ $0.64 | 2,019,563 | Feb 8, 2024 |
| Atlas Venture Associates Opportunity I, L.P. | — | Sale | 1,540 @ $0.83 | 2,020,296 | Jan 11, 2024 |
| BCIP Life Sciences Associates, LP | — | Purchase | 4,011 @ $9.84 | 2,780,413 | Dec 8, 2021 |
| SV7 Impact Medicine Fund LP | — | Purchase | 312,500 @ $16.00 | 1,613,632 | Oct 26, 2021 |
| RiverVest Venture Fund IV, L.P. | — | Purchase | 250,000 @ $16.00 | 1,441,444 | Oct 26, 2021 |